Since January 1, 2021, the results of centralized procurement of coronary stents organized by the state have been implemented in many places, and the average price of coronary stents has dropped from about 13,000 yuan to about 700 yuan. According to the preset national reporting volume, 11.7 billion yuan will be saved throughout the year.

In 2020, the reform of China's drug evaluation and approval system will enter the fifth year.

According to the National Medical Products Administration, starting from January 1 next year, China will implement a batch release system for eight types of biological products, including human albumin, recombinant hepatitis B vaccine, live attenuated measles vaccine, BCG vaccine, oral live attenuated poliovirus vaccine, and the combined adsorbed pertussis, diphtheria, and tetanus vaccine. According to relevant sources, this is an important step for China's biological product management standards to align with international practices. Batch release of biological products refers to the national authority's inspection and approval of each batch of vaccines, blood products, in vitro biological diagnostic reagents used for blood screening, and other specified biological products before they are released to the market or imported.

With the rapid development of science and technology, the bioengineering and new drug markets have become exceptionally active, especially in recent years as China's pharmaceutical market gradually integrates with the global market. The biopharmaceutical industry has rapidly emerged, and under stock market speculation, the manufacturing industry, primarily based on chemical drugs, is quickly shifting towards bioengineering technology products. In today's slow progress of chemical innovative drug development, the globalization characteristics of bioengineered drugs have become increasingly prominent and have attracted more attention. Gene products are emerging like mushrooms after rain. Biotechnological drugs refer to proteins, antibodies, or other products developed using DNA recombinant technology, monoclonal antibody technology, or other new biotechnologies.

As the third year after joining the "WTO" organization, some have called this year the beginning of the "post-WTO transition period." After experiencing the adjustment period of the first two years, deep-seated issues in China's integration with the international community have gradually emerged, among which intellectual property has increasingly become an unavoidable focal issue. This year, the dispute between multinational pharmaceutical giant Pfizer and more than ten domestic pharmaceutical companies over Viagra is seen by industry insiders as a landmark event revealing the long-standing intellectual property bottleneck troubling China's pharmaceutical industry; in fact, it is an intellectual property battle. It is understood that Pfizer underwent a 10-year research process to invent Viagra.

Xinhua Net Jakarta, January 15 (Reporters Wu Qiang, Yu Qianliang) The international medical relief organization "Doctors Without Borders" reminded residents in the Aceh disaster area of Indonesia on the 15th to be cautious of tetanus infection when clearing debris. Currently, the Aceh disaster area is hot and rainy, and many decomposing corpses are still buried in the rubble. People searching for useful items in the ruins of destroyed houses are easily infected with tetanus bacteria. Officials from "Doctors Without Borders" said the organization has found 67 cases of tetanus in the city of Banda Aceh, and it is estimated that the number of tetanus infections will significantly increase in the coming days. These officials warned that even with immediate treatment, infection